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rDITORIAL COMMENT
conomic Implications
f Transesophageal
chocardiography-Guided
ardioversion of
trial Fibrillation*
ark Hlatky, MD, FACC,† Alan S. Go, MD‡
tanford and Oakland, California
schemic stroke is the most feared complication of atrial
brillation, and many studies have investigated strategies to
educe cerebral embolism. Anticoagulation with warfarin is
emarkably effective in reducing the risk of ischemic stroke
mong patients with chronic atrial fibrillation (1) and has
ecome standard therapy. More recently, four randomized
rials (2–5) have shown that a strategy of aggressive rhythm
ontrol was no better than a strategy of rate control in
reventing ischemic stroke and other adverse clinical out-
omes. Many of the ischemic strokes in patients assigned to
he rhythm control strategy in these trials occurred after
ormal sinus rhythm had been re-established and anticoag-
lation had been discontinued.
See page 1217
Cardioversion will continue to be needed for patients
ith symptoms due to atrial fibrillation, and optimal man-
gement of these individuals remains an important issue.
ardioversion increases transiently the risk of stroke, pre-
umably because of dislodgement of left atrial thrombi.
hree weeks of anticoagulation before and after cardiover-
ion has been the standard approach for patients whose
trial fibrillation has persisted for 48 h or longer (6). The
evelopment of transesophageal echocardiography (TEE)
as offered the possibility of avoiding anticoagulation before
ardioversion (7). If no clots were visible in the left atrium,
t was hypothesized that immediate cardioversion could be
erformed with a low short-term risk of stroke. The
dvantage of this strategy lies in reducing the duration of
arfarin therapy (with its attendant inconvenience and risk
f bleeding), and in allowing immediate cardioversion. The
ssessment of Cardioversion Using Transesophageal Echo-
ardiography (ACUTE) trial tested this strategy rigorously
y randomizing 1,222 patients to either TEE-guided or
onventional cardioversion (8). There was no significant
ifference in the rate of embolism between the two patient
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Health Research and Policy and Department of Medicine,
tanford University School of Medicine, Stanford, California; and the ‡Division of
Tesearch, Kaiser Permanente of Northern California, Oakland, California.roups, but the rate of any bleeding complication over the
ight-week follow-up period was halved in the TEE group
8) because of their shorter duration of warfarin therapy.
he strategy of TEE-guided cardioversion therefore ap-
ears to be a reasonable clinical alternative to preprocedure
nticoagulation. However, if long-term anticoagulation will
e recommended for most patients even after successful
ardioversion, the major advantage of the TEE-guided
pproach in shorter duration of anticoagulation would be
reatly diluted.
CONOMIC EVALUATION
ssessment of the economic consequences of clinical man-
gement strategies has become an important aspect of
linical research. Economic analyses are particularly valuable
hen performed alongside randomized clinical trials, which
re the “gold standard” of evaluation in medicine. Conse-
uently, in this issue of the Journal, the report by Klein et al.
9) from the ACUTE investigators about medical resource
se and costs in their randomized trial of TEE-guided
ardioversion is of great interest and importance. We will
rst discuss some issues in economic evaluation and then the
articular findings of the ACUTE trial.
The costs in a clinical trial can be usefully separated into
wo components: the cost of initial management strategies
nd the costs of the clinical outcomes associated with the
trategies. Initial costs are the planned and relatively pre-
ictable cost of each management strategy and are relatively
traightforward to measure. In contrast, the costs of clinical
utcomes are neither simple to measure nor readily predict-
ble, and these costs may accumulate over an extended
eriod of time. Total cost is the sum of these two compo-
ents, one of which can be measured fairly accurately, and
he other of which is measured with much more uncertainty.
OST OF THE PLANNED STRATEGIES
he alternative strategies tested in the ACUTE trial entail
redictable initial resource consumption patterns and costs.
he clinical strategies differ only before cardioversion, and
he resource comparison is basically one transesophageal
cho versus three weeks of warfarin therapy. Based on the
osts assigned to these resources by the ACUTE investiga-
ors, one TEE ($277) costs about six times more than the
ombination of three weeks of warfarin ($14.70) and three
dditional prothrombin times tests ($31.20). Although the
ost of these resources may be higher or lower in different
ractice settings, there is little doubt that the TEE strategy
as significantly higher planned costs. Nevertheless, this
ost difference is modest in size ($231) and could easily be
ecouped if later expensive complications were prevented by
EE-guided cardioversion.
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n economic evaluation of the TEE-guided and conventional
ardioversion strategies must also account for the costs of
nplanned events, such as stroke, bleeding, and TEE-related
omplications. These are all real and important costs, yet when
vent rates are low, they cannot be measured precisely. Fur-
hermore, because these complications can be very costly to
reat, even a small difference in incidence between the two
roups could completely overshadow the modest $231 differ-
nce in the cost of the planned strategies.
The cost of the clinical outcomes is measured as follows:
piqi
here qi indicates the number (quantity) of event “i,” and pi
ndicates the mean cost (price) of treating event “i.” In the
CUTE trial, the measurement of pi and qi was based on
nly a handful of events, and there was no statistically
ignificant difference in the rates of death, stroke, major
leeding, or minor bleeding between TEE-guided and
onventional cardioversion (8). There was a modest differ-
nce (p  0.03) in major plus minor bleeding in the parent
rial, but this difference is not significantly different in the
ubset of patients enrolled in the economic analysis. Thus,
he economic comparison of the clinical outcomes of these
trategies is based on a series of small and statistically
nsignificant differences. The ACUTE trial lacked sufficient
ower to measure precisely the low rates of expensive
omplications and, as a result, the cost measurements have
ery wide confidence intervals.
A second issue in the economic analysis of the ACUTE
rial is the measurement of pi: the cost weights (prices)
ssociated with the clinical events. The economic portion of
he study was restricted to the 833 patients enrolled in the
.S. clinical sites. Hospital billing data were sought from all
atients but were available from only 369 patients (44%).
ny study missing over one-half of the data loses consid-
rable credibility because the patients for whom data are
vailable may be quite different from the remaining patients.
aced with very sparse data, the investigators tried to fill the
oles by statistical imputation. Imputation is a reasonable
trategy when data are missing for only a few percent of
ubjects but not when over half the data are missing. The
osts they estimated for infrequent, expensive events like
troke ($28,200), major bleeding ($30,200), and death
$7,400) are inconsistent and measured with great uncer-
ainty. It would have been more prudent to use Medicare
RG reimbursements as price weights. Medicare DRG
eights are a credible national standard, and their use would
liminate the problems of missing billing data and insuffi-
ient numbers of events to estimate per episode costs
ccurately. Assuming a reimbursement of $5,000 for a DRG
eight of 1.00, the costs of hospitalization for a stroke
ould be $6,259, a gastrointestinal bleed would be $4,971,
nd a fatal myocardial infarction would be $7,743. If
edicare costs had been used, we suspect the TEE-guidedtrategy would have higher costs than the conventional
ardioversion strategy.
ONCLUSIONS
he data from the ACUTE trial show that: 1) the planned
osts of TEE-guided cardioversion are modestly higher
han the costs of conventional cardioversion, and 2) the
dded cost of TEE-guided therapy might be partially or
ompletely offset by savings due to fewer complications, but
he data are quite inconclusive on this question because of
he low incidence and imprecise cost estimates. Although
he authors’ statement that total costs “did not significantly
iffer” between the groups is technically correct, they lacked
ufficient statistical power to document important cost
ifferences in the range of $200 to $300.
Economic evaluations are very hard indeed when low
requency-high cost outcomes must be considered. These
re real events that cannot be ignored, and the best approach
ay be to examine datasets of sufficient size to provide
ccurate measurement of their cost and frequency (pi and
i). These analyses may need to be performed in larger
onrandomized cohorts of patients with atrial fibrillation.
ne suggestion is that clinical trials should report separately
he initial (or planned costs) and the subsequent (un-
lanned) costs so the reader can see their relative contribu-
ion to the total. Decision models and other tools can then
e applied to judge the potential cost-effectiveness of
lternative strategies (10).
eprint requests and correspondence: Dr. Mark A. Hlatky,
tanford University School of Medicine, HRP Redwood
uilding, Room 150, Stanford, California 94305-5405. E-mail:
latky@stanford.edu.
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